Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advances study located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://hanse742upd2.bimmwiki.com/user